Mobocertinib

CHEMBL4650319 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

585.7 g/mol

LogP

4.4

Phase

4

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

น้ำหนักโมเลกุล

585.7000 g/mol

LogP

4.40

TPSA

114.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Non-Small Cell Lung Cancer

กลไกการออกฤทธิ์

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C

InChI

InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)

Molecular Formula

C32H39N7O4

HBD / HBA

2 / 9

พันธะที่หมุนได้

13

อะตอมหนัก

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Mobocertinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650319. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 118607832. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Mobocertinib บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C32H39N7O4

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.